Hereditary genetic diseases, cancer, and infectious diseases are affecting global health and become major health issues, but the treatment development remains challenging. Gene therapies using DNA plasmid, RNAi, miRNA, mRNA, and gene editing hold great promise. Lipid nanoparticle (LNP) delivery technology has been a revolutionary development, which has been granted for clinical applications, including mRNA vaccines against SARS-CoV-2 infections. Due to the success of LNP systems, understanding the structure, formulation, and function relationship of the lipid components in LNP systems is crucial for design more effective LNP. Here, we highlight the key considerations for developing an LNP system. The evolution of structure and function of lipids as well as their LNP formulation from the early-stage simple formulations to multi-components LNP and multifunctional ionizable lipids have been discussed. The flexibility and platform nature of LNP enable efficient intracellular delivery of a variety of therapeutic nucleic acids and provide many novel treatment options for the diseases that are previously untreatable.
Keyphrases
- nucleic acid
- early stage
- sars cov
- global health
- fatty acid
- public health
- drug delivery
- escherichia coli
- genome wide
- machine learning
- mental health
- radiation therapy
- squamous cell carcinoma
- gene expression
- high throughput
- single molecule
- coronavirus disease
- squamous cell
- deep learning
- risk assessment
- health information
- neoadjuvant chemotherapy
- climate change
- reactive oxygen species
- locally advanced
- replacement therapy
- circulating tumor cells